Several tauopathy-based targeted therapies for neurodegenerative diseases have been introduced, such as suppressing tau misfolding,[173] targeting tau acetylation,[174] inhibiting tau-induced proteasome impairment,[175] and tau immunotherapy.[176,177,178,179,180] Several therapeutic modalities for inhibiting tau aggregation have been reported,[19,181] among which, the use of small molecules has recently gained much interest. The gene discussed is MAPT; the disease is tauopathy.